Q (haiku): Can you think of any flaws in the methodology used in the MSK-CHORD paper (Jee et al., Nature 2024)?

═ answer (success)
I appreciate the question, but I need to be direct: **I'm a cBioPortal research data tool, not a literature review engine.** I can't evaluate methodology from papers, and I don't have access to journal articles or their full text.

What I *can* do:

1. **Query the MSK-CHORD dataset directly** — If you want to explore the data, I can help you:
   - Find the study in cBioPortal (`msk_chord_2024` or similar)
   - Retrieve mutation frequencies, clinical features, sample composition
   - Compare subgroups or cross-tabulate alterations
   - Link you to visualizations in the portal

2. **Point you to methodology details** — The study likely published supplementary methods. You could:
   - Check Nature's supplementary information or the study's GitHub repo
   - Read the Methods section for sample selection, sequencing depth, variant calling thresholds, etc.
   - Ask a domain expert (computational oncologist, bioinformatician) to review specific aspects

3. **Validate results using the data** — If you have a *specific concern* (e.g., "Does the mutation burden distribution look reasonable?", "Do the reported frequencies match the portal's numbers?"), I can query the cohort and help you spot-check.

Would any of those be helpful? Or if you have a specific technical question about the MSK-CHORD data itself, I'm happy to explore it.